Lung Cancer Research Foundation Awards $1.5 Million Grant for HER2 Mutation Study
The Lung Cancer Research Foundation (LCRF) has announced the recipients of its Team Science Award, a $1.5 million grant aimed at developing innovative therapeutic strategies for lung cancers with HER2 mutations. The project, led by Dr. John Heymach from the University of Texas MD Anderson Cancer Center, focuses on understanding and overcoming resistance to current treatments in non-small cell lung cancer (NSCLC) patients with HER2 mutations. Despite recent advancements with HER2-targeted therapies, many patients experience relapse due to resistance. The research team, which includes experts from Harvard Medical School, NASA Ames Research Center, and the Broad Institute of MIT and Harvard, will employ a multidisciplinary approach using deep mutational scanning, structural biology, and computational modeling to address these challenges. 
